%PDF-1.3
%âãÏÓ
1 0 obj
<<
/OPM 1
/Type/ExtGState
>>
endobj
2 0 obj
<<
/FL 1
/SM 0.01
/Type/ExtGState
>>
endobj
3 0 obj
<<
/Length 9980
>>
stream
/GS0 gs
q
0 0.89 595 841 re
W n
1 g
0 841.89 0 0 re
f
Q
/GS1 gs
q
0 0 0 0 k
56.693 140.0411 481.89 469.408 re
f
Q
q
BT
/F0 1 Tf
9 0 0 9 146.5879 601.4311 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(SUMMARY)Tj
-8.41504 -2.22222 TD
-0.0001 Tc
(H)Tj
0.77793 0.00001 TD
0 Tc
(BsAg seroconversion with convensional interferon )Tj
3.6116 -1.11112 TD
(treatment for chronic hepatit B)Tj
ET
Q
q
BT
/F1 1 Tf
9 0 0 9 57.6929 551.4312 Tm
0 Tr
0 0 0 1 k
0.011 Tc
0.114 Tw
(Each year HBsAg clearance appears spontenously between)Tj
0 -1.11112 TD
0 Tc
0.049 Tw
(the range of 1-2 percent of hepatit B and, also antiHBs appe-)Tj
0 -1.11111 TD
0.101 Tw
(ars in 1/3 rate of these cases. HBsAg serokonversion is seen)Tj
T*
0.001 Tc
0.124 Tw
(in 4 percent of patients treated with convensional interferon)Tj
T*
0 Tc
0.053 Tw
(and this rate is also similar for the treatment with peginterfe-)Tj
T*
0.034 Tw
(ron. We present a case who cleared HBsAg and achieved anti)Tj
0 -1.11112 TD
0 Tw
(HBs positivity after treatment with convensional interferon. )Tj
ET
Q
q
BT
/F2 1 Tf
9 0 0 9 57.6929 471.4312 Tm
0 Tr
0 0 0 1 k
0 Tc
0.084 Tw
(Key words:)Tj
ET
Q
q
BT
/F1 1 Tf
9 0 0 9 102.7041 471.4312 Tm
0 Tr
0 0 0 1 k
0 Tc
0.084 Tw
(Chronic hepatit B, convensional interferon treat)Tj
19.75174 0 TD
(-)Tj
-24.75299 -1.11112 TD
0 Tw
(ment, HBsAg seroconversion)Tj
ET
Q
q
BT
/F2 1 Tf
9 0 0 9 57.6929 441.4312 Tm
0 Tr
0 0 0 1 k
0 Tc
0.056 Tw
(Anahtar kelimeler:)Tj
ET
Q
q
BT
/F1 1 Tf
9 0 0 9 131.6998 441.4312 Tm
0 Tr
0 0 0 1 k
0 Tc
0.056 Tw
(Kronik hepatit B, interferon tedavisi, anti)Tj
-8.22299 -1.11111 TD
0 Tw
(HBs pozitifle\337mesi)Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 57.6929 392.4311 Tm
0 Tr
0 0 0 1 k
0 Tc
0.033 Tw
[(Hepatit B vir\237s\237 birincil)-283(karaci\333er habasetlerinin \(hepa)-1(-)]TJ
0 -1.3 TD
0.028 Tw
(tosel\237ler kanser\) % 60 ile % 80\325inden sorumludur. Kro-)Tj
T*
0.024 Tw
[(nik hepatit B' li hastalar\335n % 25\325i birincil)-274(karaci\333er kan-)]TJ
T*
0.014 Tw
(seri ve siroz nedeniyle \232lmektedir. Bu durum kronik he-)Tj
T*
0.001 Tc
0.124 Tw
(patit B hastal\335\333\335nda tedavinin \232nemini belirlemektedir.)Tj
0 -1.30001 TD
0 Tc
0.033 Tw
(Kronik hepatit B hastalar\335nda interferon tedavisine kal\335-)Tj
0 -1.3 TD
0.0311 Tc
<63DD>Tj
1.15921 0 Td
0.031 Tc
0.094 Tw
(yan\335t en fazla tedavi \232ncesi ALT d\237zeyi y\237ksek,)Tj
-1.15921 -1.3 TD
0 Tc
0.028 Tw
(HBV DNA d\237zeyi d\237\337\237k hastalarda elde edilmi\337tir. Ka-)Tj
T*
0.009 Tc
0.116 Tw
(l\335c\335 yan\335t\335n al\335nd\335\333\335 hastalarda da 2 y\335ll\335k izlem sonu-)Tj
T*
0 Tc
0.04 Tw
(cunda da yan\335t\335n b\237y\237k oranda devam etti\333i bildirilmi\337-)Tj
T*
0.018 Tw
(tir. Biz de kronik hepatit B de tedavi ile az oranda g\232r\237-)Tj
T*
0.023 Tw
[(len HBsAg serokonversiyonu sa\333lanan bir olguyu)-273(sunu-)]TJ
T*
0 Tw
(yoruz.)Tj
ET
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 210.4311 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(OLGU)Tj
ET
Q
q
BT
/F3 1 Tf
9 0 0 9 57.6929 187.4311 Tm
0 Tr
0 0 0 1 k
0 Tc
0.088 Tw
(68 ya\337\335nda bayan hasta 2002 y\335l\335 ortalar\335nda serum transami-)Tj
0 -1.11111 TD
0.102 Tw
(naz d\237zeyleri y\237ksek bulunarak gastroenteroloji poliklini\333ine)Tj
T*
0.052 Tw
(ba\337vurdu. Transaminaz y\237ksekli\333i a\215\335s\335ndan etiyolojiye y\232ne-)Tj
0 -1.11111 TD
0.071 Tw
(lik yap\335lan ara\337t\335rmalar sonucunda hastan\335n HbsAg pozitifli\333i)Tj
0 -1.11111 TD
0.045 Tw
(saptand\335. Alt\335 ay boyunca transaminaz y\237ksekli\333i devam eden)Tj
28.23535 50.3586 TD
0.092 Tw
(hastan\335n HBV DNA vir\237s y\237k\237 3x10)Tj
ET
Q
q
BT
/F3 1 Tf
7 0 0 7 449.6867 602.9684 Tm
0 Tr
0 0 0 1 k
0 Tc
(5)Tj
ET
Q
q
BT
/F3 1 Tf
9 0 0 9 456.2667 600.6584 Tm
0 Tr
0 0 0 1 k
0 Tc
0.092 Tw
((3x100.000) kopya/ml)Tj
-16.05063 -1.11111 TD
-0.0001 Tc
(b)Tj
0.49993 0.00001 TD
0 Tc
0.035 Tw
(ulundu. Hasta 6 ayl\335k izlem sonunda mutant tip kronik hepa-)Tj
-0.49993 -1.11111 TD
0.0079 Tc
(t)Tj
0.28592 0.00001 TD
0.008 Tc
0.117 Tw
(it B (HBeAg negatif ve anti HBe pozitif) infeksiyon kabul)Tj
-0.28592 -1.11112 TD
0 Tc
0.006 Tw
(edilip karaci\333er bi)Tj
7.28524 0 TD
[(yopsisi yap\335ld\335.)-256(Karaci\333er i\333ne biyopsi pato-)]TJ
-7.28524 -1.11112 TD
0.013 Tc
0.112 Tw
(loji raporu kronik hepatit B, orta \337iddette aktivite \(Knodell)Tj
0 -1.11111 TD
-0.0001 Tc
(HAI)Tj
2.02668 0 Td
0 Tc
0 Tw
(skoru 13\), evre 2 fibrozis ile uyumlu geldi. )Tj
-2.02668 -2.22223 TD
0.03 Tw
(Hastaya interferon tedavisi uygulanmas\335na karar verildi. Ekim)Tj
0 -1.11111 TD
0.025 Tw
(2003-Ekim 2004 tarihleri aras\335nda haftada 30 m\237 konvansiyo-)Tj
0 -1.11112 TD
0.03 Tw
(nel interferon alfa 2b tedavisi yap\335ld\335. Tedavi s\335ras\335nda transa)Tj
24.753 0 TD
(-)Tj
-24.753 -1.11112 TD
0.121 Tw
(minazlar 2. aydan itibaren s\237rekli normal seyretti. Tedavinin)Tj
0 -1.11111 TD
0.023 Tc
0.102 Tw
(4. ay\335nda likid hibridizasyon ile yap\335lan test sonucu HBV)Tj
T*
0.018 Tc
0.107 Tw
[(DNA negatif idi \(Cut-)1(off de\333er 5 pg/ml\))1(.)-374(T)1(e)1(d)1(a)1(v)1(i)1( )1(s)1
1(r)1(a)1(s)11(n)1(d)1(a)]TJ
T*
0 Tc
0.007 Tw
(hastada interferon tedavisine )Tj
11.76382 0 TD
0 Tw
(ikincil)Tj
2.81181 0 TD
(depresyon)Tj
4.10938 0 TD
(,)Tj
0.50664 0 TD
0.007 Tw
(i\337tahs\335zl\335k, v\237)Tj
5.56133 0 TD
(-)Tj
-24.75298 -1.11113 TD
0.122 Tw
[(cut a\333\335rl\335\333\335nda 4 kg)-372(azalma g\232r\237ld\237, fakat ila\215 istenilen s\237re)]TJ
0 -1.11111 TD
0 Tw
(ve dozda kullan\335labildi. )Tj
0 -2.22222 TD
0.047 Tw
[(Tedavi sonras\335 6. ayda HBV DNA 4080 kopya/ml)-297(olan hasta-)]TJ
0 -1.11111 TD
0.053 Tw
(n\335n transaminazlar\335 s\237rekli normal d\237zeylerde idi. HBV DNA)Tj
-0.0001 Tc
(6)'
0.79541 0 Td
0 Tc
0.046 Tw
(ayda bir kontrol edildi. 2 kez 10)Tj
ET
Q
q
BT
/F3 1 Tf
7 0 0 7 436.6463 412.9684 Tm
0 Tr
0 0 0 1 k
0 Tc
(2)Tj
ET
Q
q
BT
/F3 1 Tf
9 0 0 9 442.8063 410.6584 Tm
0 Tr
0 0 0 1 k
0 Tc
0.046 Tw
(ile 3 x10)Tj
ET
Q
q
BT
/F3 1 Tf
7 0 0 7 475.1217 412.9684 Tm
0 Tr
0 0 0 1 k
0 Tc
(5)Tj
ET
Q
q
BT
/F3 1 Tf
9 0 0 9 481.2816 410.6584 Tm
0 Tr
0 0 0 1 k
0 Tc
0.046 Tw
(aras\335 kopya/ ml)Tj
-18.83006 -1.11111 TD
0.003 Tc
0.122 Tw
(bulundu. Tedavi sonras\335 ikince y\335lda HBV DNA negatif idi.)Tj
T*
0 Tc
0.047 Tw
(Bu arada HBsAg de\333erinin de negatif bulunmas\335 \237zerine Anti)Tj
T*
0 Tw
(HBs bak\335ld\335. AntiHBs 9.5 pg/m)Tj
12.66626 0 TD
-0.0001 Tc
(l)Tj
0.52783 0 Td
(b)Tj
0.49999 0 TD
0 Tc
(orderline bulundu.)Tj
-13.69409 -2.22223 TD
0.073 Tw
(Hasta tedaviye yan\335tl\335 olup HBsAg serokonversiyonu da g\232z-)Tj
0 -1.11111 TD
0.05 Tw
(lenen kronik hepatit B kabul edildi. Antikor d\237zeyini y\237kselt)Tj
24.753 0 TD
(-)Tj
-24.753 -1.11111 TD
0 Tw
(mek i\215in hasta a\337\335lama program\335na al\335nd\335.)Tj
ET
Q
q
BT
/F0 1 Tf
10 0 0 10 311.811 314.6584 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(TARTI\336MA)Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 311.811 288.6584 Tm
0 Tr
0 0 0 1 k
0.014 Tc
0.111 Tw
(\334nterferonlar \215e\337itli h\237crelerde bulunan resept\232rlerine)Tj
0 -1.3 TD
0.025 Tc
0.1 Tw
(ba\333lanarak anti viral ve imm)Tj
12.60193 0.00001 TD
[<9F6E>-376(mod\237lat\232r etkilerini)]TJ
-12.60193 -1.30001 TD
0 Tc
0.019 Tw
[(ba\337lat\335rlar; makrofajlar, do\333al \232ld\237r\237c\237)-270(h\237creler ve sito-)]TJ
0 -1.3 TD
0.107 Tw
(toksik T h\237crelerin aktivitesini art\335rarak virusla infekte)Tj
T*
0.113 Tw
(h\237crelerin eliminasyonunu sa\333larlar. \334nterferonlar vir\237-)Tj
T*
0.115 Tw
(s\237n h\237cre i\215ine giri\337ini ve viral RNA protein sentezini)Tj
T*
0.032 Tw
(inhibe ederler )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 370.1999 213.2984 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((1,3))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 385.5242 210.6584 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
0.53223 0.00001 TD
Tj
0.33277 0.00001 TD
0.032 Tw
(nterferonlar\335n imm\237n)Tj
8.89406 0.00001 TD
(mod\237lat\232r et)Tj
5.11403 0.00001 TD
(-)Tj
-22.24441 -1.30003 TD
0.116 Tw
(kilerini; h\237cresel imm\237nite ve antikor sentezini d\237zen-)Tj
0 -1.3 TD
0.01 Tc
0.115 Tw
(leme, antijenlerin ekspresyonu ve tan\335nmas\335n\335 art\335rma)Tj
T*
0.006 Tc
0.118 Tw
[(d)-1(o)-1-1(a)-1(l)-1( )-1<9A>-1(l)-1(d)-1<9F>-1(r)-1<9F>-1(c)-1<9F>-376(h\237cre aktivitesini art\335rma, h\237cre y\237ze-)]TJ
T*
0 Tc
0.035 Tw
(yindeki major histokompatabilite antijenlerinin ekspres-)Tj
T*
0.03 Tc
0.095 Tw
(yonunu art\335rarak yaparlar )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 426.5454 148.2984 Tm
0 Tr
0 0 0 1 k
0.03 Tc
0 Tw
((1,2))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 443.0662 145.6584 Tm
0 Tr
0 0 0 1 k
0.0299 Tc
(.)Tj
0.65492 0 Td
0.03 Tc
0.095 Tw
(\334nterferonlar normal)Tj
ET
0 0 0 0 k
56.693 634.502 481.89 94.002 re
f
Q
q
BT
/F0 1 Tf
20 0 0 20 57.6929 712.5873 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Kronik hepatit B\325de konvansiyonel interferon )Tj
0 -1.1 TD
(tedavisi)Tj
ET
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 638.5873 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Feruze YILMAZ EN\202 (*), Canan YE\336\334LO\332LU (*))Tj
ET
0 J 0 j 10 M []0 d 1 w
0 0 0 1 K
56.693 623.5471 m
538.583 623.5471 l
S
0 0 0 0 k
56.693 119.055 481.89 10.174 re
f
Q
q
BT
/F3 1 Tf
8 0 0 8 57.6929 121.9651 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(G\232ztepe E\333itim Ara\337t\335rma Hastanesi Gastroenteroloji Bilim Dal\335, Dr.*)Tj
ET
0 J 0 j 10 M []0 d 1 w
0 0 0 1 K
56.693 133.229 m
538.583 133.229 l
S
57.78 755.355 m
539.669 755.355 l
S
0 0 0 0 k
56.693 752.851 481.89 13 re
f
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 757.021 Tm
0 Tr
0 0 0 1 k
0.1 Tc
0 Tw
(OLGU SUNUMU)Tj
ET
Q
q
BT
/F3 1 Tf
10 0 2.12557 10 456.1927 757.021 Tm
0 Tr
0 0 0 1 k
0.1 Tc
0 Tw
(Gastroenteroloji)Tj
ET
0 J 0 j 10 M []0 d 1 w
0 0 0 1 K
56.693 748.351 m
538.583 748.351 l
S
56.693 771.024 m
538.583 771.024 l
S
56.693 415.347 m
283.465 415.347 l
S
0 0 0 0 k
56.693 789.197 136.063 10.173 re
f
Q
q
BT
/F1 1 Tf
8 0 0 8 57.6929 792.4114 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
[(G\232ztepe T\335p Dergisi 21(3):)-1(107-108, 2007)]TJ
ET
0 0 0 0 k
470.551 788.1971 68.027 11.1729 re
f
Q
q
BT
/F0 1 Tf
9 0 0 9 471.551 791.6577 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(ISSN 1300-526X)Tj
ET
0 0 0 0 k
521.575 92.168 17.0079 12.714 re
f
Q
q
BT
/F0 1 Tf
10 0 0 10 522.5748 96.4236 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(107)Tj
ET
Q
endstream
endobj
4 0 obj
<<
/Length 3850
>>
stream
/GS0 gs
q
0 0.89 595 841 re
W n
1 g
0 841.89 0 0 re
f
Q
/GS1 gs
q
0 0 0 0 k
56.693 560.055 481.89 196.796 re
f
Q
q
BT
/F3 1 Tf
10 0 0 10 57.6929 748.021 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(h)Tj
0.49988 0.00001 TD
0 Tc
0.051 Tw
(\237crede reversibl, neoplazik h\237crede irreversibl sitostaz)Tj
-0.49988 -1.30001 TD
0.014 Tc
0.111 Tw
(yaparlar. Onkojen vir\237slerin transforme edici etkisini)Tj
0 -1.3 TD
0.0018 Tc
(i)Tj
0.27982 0.00001 TD
0.002 Tc
0.123 Tw
(nhibe ederler. Birden fazla mekanizmaya ba\333l\335 olarak)Tj
-0.27982 -1.30001 TD
0 Tc
0.056 Tw
(geli\337en antiproliferatif etki ile HBV\325ye ba\333l\335 olu\337an he-)Tj
0 -1.3 TD
0 Tw
(patosel\237ler karsinom geli\337imini \232nleyebilirler )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 242.6319 698.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((4))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 251.9561 696.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-19.42632 -2.6 TD
0.004 Tw
[(\334nterferon,)-254(alfa 2b kronik hepatit B ve erken sirozlu has-)]TJ
0 -1.3 TD
0.081 Tw
(talar\335n tedavisinde kullan\335lmaktad\335r. Kronik hepatit B'li)Tj
T*
0.004 Tw
(olgularda \337u anki tedavi stratejisi 4-6 ayl\335k interferon al-)Tj
T*
0.002 Tc
0.123 Tw
(fa 2b ile tedavi sonucunda; transaminazlar\335 normalle\337-)Tj
T*
0.005 Tc
0.12 Tw
[(tirmesi, HBV DNA negatifli)11(i, hepatik inflamasyonda)]TJ
T*
0 Tc
0 Tw
(azalma, muhtemel siroza gidi\337in yava\337lamas\335d\335r.)Tj
0 -2.6 TD
0.09 Tw
(Konvansiyonel interferon tedavisi alan hastalarda mey-)Tj
0 -1.3 TD
0.026 Tc
0.099 Tw
(dana gelen HBsAg serokonversion oran\335n\335n spontan)Tj
25.41181 18.19999 TD
-0.0001 Tc
(o)Tj
0.49991 0.00001 TD
0 Tc
0.014 Tw
(lu\337an serokonversion oran\335ndan fazla olmas\335 nedeni ile)Tj
-0.49991 -1.30001 TD
0.011 Tc
0.114 Tw
(interferon tedavisini anlaml\335 k\335lmaktad\335r. G\237n\237m\237zde)Tj
0 -1.3 TD
-0.0001 Tc
(p)Tj
0.49989 0.00001 TD
0 Tc
0.101 Tw
(egile edilmi\337 interferonlar kullan\335larak hastan\335n hafta-)Tj
-0.49989 -1.30001 TD
0.024 Tw
(da bir kez subk\237tan enjeksiyonu ile tedaviye uyumu ko-)Tj
0 -1.3 TD
0 Tw
(layla\337t\335r\335lm\335\337t\335r. )Tj
ET
Q
q
BT
/F0 1 Tf
10 0 0 10 311.811 670.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(KAYNAKLAR)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 649.021 Tm
0 Tr
0 0 0 1 k
0.005 Tc
0.119 Tw
(1. Eddleston ALWF and Dixon B:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 436.4809 649.021 Tm
0 Tr
0 0 0 1 k
0.005 Tc
0.119 Tw
(Interferons in the treatment of)Tj
-15.58373 -1 TD
0 Tc
0 Tw
(chronic viral infection of liver, 1. edit, UK, pennine pres 1990.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 633.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.09 Tw
(2. Dianzani F Antonelli G, Capobianchi MR:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 471.719 633.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.09 Tw
(The biological basis)Tj
-19.9885 -1 TD
0 Tw
(fort he clinical use of interferon. J Hepatol (suppl 1):5-10, 1990.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 617.0211 Tm
0 Tr
0 0 0 1 k
0 Tc
0.026 Tw
(3. Rogers et al:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 365.7344 617.0211 Tm
0 Tr
0 0 0 1 k
0 Tc
0.026 Tw
(Hepatitis B vir\237s: Clinical disease. Richard AW (ed).)Tj
-6.74042 -1 TD
0 Tw
(Viral Hepatitis,1. edit, NewYork, Marcel Dekker 1997: 134-46.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 601.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.019 Tw
(4. \334keda K, Saitoh S, Suzuki Y, et al:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 439.587 601.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.019 Tw
(Interferon decreases hepatoce-)Tj
-15.972 -1 TD
0.091 Tw
(l\237ler carcinogenesis in patients with cirrhosis caused by the hepatitis)Tj
-0.0001 Tc
(B)'
0.91689 0 Td
0 Tc
0 Tw
(vir\237s: a pilot study. Cancer 82:887-35, 1998.)Tj
ET
0 0 0 0 k
402.52 789.197 136.063 10.173 re
f
Q
q
BT
/F1 1 Tf
8 0 0 8 403.5198 792.4114 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
[(G\232ztepe T\335p Dergisi 21(3):)-1(107-108, 2007)]TJ
ET
0 0 0 0 k
56.693 92.168 17.008 12.714 re
f
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 96.4236 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(108)Tj
ET
Q
endstream
endobj
5 0 obj
<<
/Nums[0<>]
>>
endobj
6 0 obj
<<
/Differences[32/space 40/parenleft/parenright/asterisk 44/comma/hyphen/period 48/zero/one/two/three/four/five/six/seven/eight 58/colon 65/A/B/C/D/E/F/G/H/I 75/K/L/M/N/O 82/R/S/T/U 87/W/X/Y/Z 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p 114/r/s/t/u/v/w/x/y/z 130/Ccedilla 213/quoteright 218/fraction 220/guilsinglleft 222/fi]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
7 0 obj
<<
/Subtype/Type1C
/Length 8307
/Length1 8307
>>
stream
REIZXQ+TimesTurkB ?ø øøøøRû”ú„úY
‹‹
‹‹ ¹ µ B‘ m %DNMacromedia Fontographer 4.1.5 4/1/99Generated by Fontographer 4.1.5TimesTurkB C 4 6 . " 3 : ) # T H F S P D O W J X U I B M G N Q 0 - ( 5 * m , L E Z ' V [ ; &